- €48.78bn
- €44.92bn
- $4.15bn
Brief: Argenx, Zai Lab Announce Approval Of Efgartigimod Alfa Injection For Generalized Myasthenia Gravis In China
Brief: Zai Lab And Argenx Announce Approval Of Efgartigimod Alfa Injection For Generalized Myasthenia Gravis In China
Europe Research Roundup: Admiral, Maersk, Raspberry PI
Argenx jumps after FDA okays its neuromuscular disorder drug
Brief: Argenx Announces FDA Approval Of Vyvgart Hytrulo For Chronic Inflammatory Demyelinating Polyneuropathy
Europe Research Roundup: Adidas AG , Crest Nicholson Holdings , Standard Chartered
Argenx up 7% as rival Biohaven drug study disappoints
Europe Research Roundup: Argenx, Hermes, National Grid
Brief: Argenx Expects Combined 2024 R&D and SGA Expenses Of Less Than $2 Bln
Brief: Argenx Q1 Net Income USD -61.597 Million
Brief: Argenx Shares Data From Phase 3 Trial For Vyvgart And Vyvgart Hytrulo
Plans to pursue efgartigimod development in SjD lift argenx shares
Brief: Argenx Advances Clinical Development Of Efgartigimod In Primary Sjogren’s Disease
Immunovant and Argenx rise as rival Chugai's data fails to impress
Europe Research Roundup: Colonial, Covivio SA, Fluidra SA
Brief: argenx Says Q4 Net Loss Was $99 Million
Brief: Argenx Q4 Net Income USD -99.172 Million
Brief: Argenx Announces FDA Acceptance Of Supplemental Biologics License Application With Priority Review For Vyvgart Hytrulo
Piper Sandler raises argenx PT on potential of neurological treatments